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Summary Gene-transfected tumour cells were used to cure mice bearing lung metastases by the parental, non-
transduced mammary adenocarcinoma (TSA-pc). Repeated subcutaneous (s.c.) administrations ofmitomycin C
(MitC)-treated interferon y (IFN-y) transfectants induced a 90% inhibition in the number of lung metastases.
Therapeutic effect required an intact T-cell response, as shown by the lack of efficacy in nude mice. Autocrine
stimulation by IFN-y induces specific modifications in the phenotype of transfectants that acquire a high
metastatic ability and show a high expression of IFN-responsive genes; these two features were exploited to
design two experimental protocols to obtain an improvement of the therapeutic effect. The increased metastatic
ability of IFN-y transfectants was used to deliver IFN-y selectively to the lungs of mice bearing TSA-pc
pulmonary metastases. A significant therapeutic effect was obtained when TSA-pc experimental metastases
were treated by repeated intravenous (i.v.) injections of MitC IFN-y transfectants. Since i.v. administrations of
IFN-y transfectants did not induce immune memory, the therapeutical effect appeared to depend on the
inflammatory-like response activated by local IFN release. To exploit the autocrine stimulation of IFN-
sensitive genes an IFN-y transfectant clone was subjected to a second transfection with an allogeneic class I
MHC gene (H-2Kb or H-2Db). IFN-y plus MHC double transfectants maintained IFN-y release, showed a very
high expression of the MHC gene products, stimulated both macrophages and T cells, and were less
tumorigenic in immunocompetent mice than the parent IFN-y clone. Therapeutic efficacy of double
transfectant IFN-y plus H-2Db cells against TSA-pc was superior to single transfectants, showing that the
reaction elicited by genetically engineered cells can be selectively tuned to increase therapeutic efficacy.
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The use of gene transduction has considerably expanded the
range of tools available for the immunotherapy of tumours.
Protection from tumour growth in preimmunised animals has
been obtained with tumour cells transduced with genes for
various cytokines and surface antigens (Tanaka et al., 1986;
Ostrand-Rosenberg et al., 1991; Colombo and Forni, 1994).
However, realistic therapeutic protocols, in which engineered
cells are administered only after the challenge with live parent
tumour cells, have been explored less frequently.
Malignant tumour cells transduced with foreign genes are
a complex biological reagent. In fact, they should be regarded
as a novel type of tumour, rather than as a passive
immunological vaccine. In particular, some of the cytokines
used for this type of studies are active both on the host
immune system and on the tumour itself. In particular,
interferon (IFN) gene transduction profoundly alters several
properties of the transformed cells, including upmodulation
of MHC, resistance to natural killer (NK) cells and
metastatic ability (Watanabe et al., 1989; Gansbacher et al.,
1990; Restifo et al., 1992; Lollini et al., 1993).
In principle, genes coding for class I major histocompat-
ibility complex (MHC) should modify the interaction of
tumour cells with the immune system only, but it has been
clearly shown that after transfection of MHC genes a few
properties of the neoplastic cells are also modified (De
Giovanni et al., 1994).
These considerations suggest that the biological properties
of recipient tumour cells must be adequately characterised,
before and after gene transfer, to exploit the possibilities
offered by this technology fully. In this work we show how to
take advantage for therapeutic purposes of some specific
modifications induced by transfection of the IFN-y gene in a
mammary carcinoma.
Materials and methods
Cells and DNA transfection
TSA-pc is a tumour cell line we derived from a spontaneous
mammary adenocarcinoma of the BALB/c strain; TSA-pc
cells give rise to moderately differentiated, non-capsulated
invasive tumours, which are highly metastatic and poorly
immunogenic in syngeneic mice (Lollini et al., 1993). TSA-pc
has been used as the recipient of several cytokine genes
(Colombo and Forni, 1994), including IFN-y (Lollini et al.,
1993). TSA-IFNy500 and TSA-IFNy"0 were obtained from
TSA following gene transfection with the murine IFN-y gene
and release 500 and 6000 IU ml-' of IFN-y (Lollini et al.,
1993); TSA-neo control was transfected with the neomycin
resistance gene alone (Lollini et al., 1993). Clone TSA-
IFNy6" was subsequently transfected with allogeneic H-2K'
and H-2Db genes (Lollini et al., 1995) to obtain clones
designated TSA-IFNy'-Kb or TSA-IFNy'0-Db. Hygro-
mycin resistance was used to select transfectants; clone TSA-
IFNy610 -hygro was transfected with the hygromycin
resistance gene alone. Cells were cultured in Dulbecco's
modified eagle medium (DMEM; Gibco, Paisley, UK),
supplemented with 10% heat-inactivated fetal bovine serum
(FBS; Gibco); cultures were maintained at 37°C in a
humidified atmosphere of 5% carbon dioxide in air. All
the cells employed were >90% viable as judged by trypan
blue dye exclusion.
Mice and TSA-pc challenge
Seven-week-old female BALB/cAnNCrlBR (BALB/c) mice
and 4-week-old female nu/nu mice on Swiss CD-1 back-
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ground were purchased from Charles River Laboratories
(Calco, Italy) and treated according to European Community
guidelines. Mice were allowed to rest for I week before any
treatment. Metastases were induced by i.v. injection of TSA-
pc cells in a lateral tail vein (5 x 104 cells in BALB/c mice or
5 x 105 cells in nude mice). Lung nodules were evaluated at
day + 21; all metastasis counts were performed on dissected
lung lobes contrasted with black India ink under a
stereoscopic microscope.
Tr-eatment
Either before or after the TSA-pc challenge, mice received
transfectants treated with 60 jig ml-' mitomycin-C (Sigma,
Milan, Italy) at 37°C for 45 min to abolish their residual
tumorigenicity (Allione et al., 1994). Prophylactic vaccina-
tions consisted of a single injection of I x 106 mitomycin-C-
treated (MitC) cells performed 30 days before challenge.
Therapeutic vaccinations started 1 day after TSA-pc
challenge and consisted of six injections of 1 x 106 MitC
cells 3-4 days apart.
In vitro c'totoxicitv tests
Cytotoxicity was tested using lymph node (axillary, inguinal
and mesenteric) cells or macrophages from mice repeatedly
immunised with 1 x 106 MitC cells s.c. In some experiments,
effectors were restimulated by a 6 day in 'itro coculture with
MitC TSA-pc cells and then tested for cytotoxic activity. Target
cells were labelled by incubating non-confluent monolayers in
25 cm2 tissue culture flasks for 24 h with 5 ml of medium
containing I jtCi ml-' [-H]thymidine (26 Ci mmol-'; NEN,
Milan, Italy). Target cells were then harvested by trypsin-
EDTA (Gibco) treatment, washed twice and resuspended to a
concentration of 5 x 104 cells ml in the test medium. Effector
cells were admixed in triplicate with 5 x 10' labelled target cells
at 50: 1, 25:1, 12: 1 and 6: 1 E: T ratios in round-bottomed 96-
well microtitre plates. After 48 h incubation at 37°C in 5%
carbon dioxide, 0.1 ml of the supernatant was taken and the
percentage of specific lysis was calculated as previously
described (Lollini et al., 1993). In some experiments, 5"Cr-
labelled TSA-pc cells were also used to evaluate 4 h release in
the presence ofeffectors obtained as above, but very low values
ofcytotoxicity were obtained owing to the resistance to lysis of
TSA-pc target cells (data not shown). Maximum release was
determined by adding 0.1 ml of 10% Triton X-100. Values of
spontaneous release were within 10- 15%. The release values
are expressed as lytic units (LU) calculated as described (Lollini
et al., 1993). One LU is here defined as the number of effector
cells needed to kill 20% of the target cells (LU20).
a
Statistical anal'.sis
The non-parametric Wilcoxon's rank-sum test was used to
compare numbers of metastases.
Results
Inmnmunogenicitv of TSA-IFN- clones
TSA-pc is a highly malignant tumour, and expression of the
IFN-j; gene did not abolish completely the tumorigenicity of
clones TSA-IFN;500 and TSA-IFN-.6"". (which release 500 and
6000 IU ml-' IFN-; respectively), thus mitomycin-C-treated
(MitC) cells were used for therapeutic administrations. MitC
cells retain for several days the ability to release IFN-j;, as
shown by reverse transcriptase -polymerase chain reaction
and IFN-; bioassay (data not shown).
We have previously shown that the reduced tumorigenic
potential of IFN-; clones was mainly caused by the local
activity of macrophages. However, tumour infiltrate also
contained activated lymphocytes (Lollini et al., 1993). IFN-,
clones induced memory cells directed against the parent
tumour TSA-pc; mice immunised with IFN-; clones were
protected against a subsequent challenge with TSA-pc
(Musiani et al., 1994). Mice immunised with TSA-IFN;500
or TSA-IFN-6"00 displayed a stronger cytotoxicity against
TSA-pc than mice immunised with TSA-pc or TSA-neo
(Figure 1).
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Figure 1 Lysis of TSA-pc by restimulated lymph node cells from
BALB c mice immunised s.c. in the right thigh with 106 MitC
cells.
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Figure 2 Therapy of TSA-pc lung metastases with IFN-;! transfectants. BALB c mice challenged with 5 x 104 live TSA-pc cells i.v.
received six injections of 106 MitC cells s.c. in a thigh. (a) Metastasis-free mice, number of treated mice. (b) Range of lung
metastases. *Number of metastases significantly different (P<0.01 at least) from untreated or TSA-pc-treated mice by Wilcoxon's
rank-sum test.
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Therapy of' bIllg nctitasases
The ability of IFN-,' clones to enhance macrophage activity
(Lollini t al-. 1993) anid to elicit memory cells suggests that
these clones could be used for immunotherapy. Since a maLjor
goal of caLncer immunotherapy is to prevent the development
of overt metastases in tumour-free hosts, BALB c mice were
first challenged i.v. with TSA-pc cells and then repeatedly
treated s.c. with MitC TSA-IFN; clones (Figure 2). Therapy
with IFN-; clones yielded more than one-third of mice free
fi-om lung metastases and reduced by 90% the median
numuber of metastatic foci per mouse.
The lack of' therapeutic efficacy of IFN-, transfectant cells
inl nude mice (Figure 3), comppared with immunocompetent
hosts (see Figure 2), showed that an intact T-cell response is
required for the cure of lung metastases.
SCl'lltal'gC'tiI7gr *)f tI'bl1,SIc'c'tan/ts
The treatimienit of tumour cells with IFN-, enhances their
SUrI-vival in the post-intravasation phases of the metastatic
process, probably through an increase in resistance to NK
cells (Kelly et al., 1991). TSA-IFN-'"` and TSA-IFN,6""".
even though they have a reduced tumorigenic potential
compai-ed with TSA-pc, aieC more metastatic after i.v.
injection (Lollini et al., 1993). However, this higher
metastatic capacity of TSA-IFN; clones could be exploited
for- a selective delivery of IFN-,-releasing cells to the lung,
where TSA-pc mietastasises.
a
Therefore, the therapeutic effect of IFN-j' clones adminis-
tered i.v., a route which is not commonly used for
immunotherapy in mice, was next evaluated. First, the
immune memory against TSA-pc experimental metastasis
elicited by MitC IFN-; clones injected i.v. was evaluated. The
preimmunisation (day -30) with either MitC TSA-pc or
IFN-, clones did not elicit protection against a TSA-pc i.v.
challenge (day 0) (data not shown). By contrast, when MitC
TSA-IFN-; clones were administered i.v. after an i.v. TSA-pc
challenge, a significant inhibition in the number of lung
nodules was found (Figure 4). On the other hand, the same
treatment with MitC TSA-pc actually enhanced the
development of metastases. Taken together, these results
suggest that the IFN--, released by transfectants in the lungs
acts via inflammatory, rather than memory, components.
Therajlipy oftwllig colonies ii'itlh IFN-; pllis H-2"' double
tr-ats/cctanits
The results with IFN-;, clones were encouraging, especially
considering that TSA is a highly malignant tumour.
However, to potentiate further the interactions of tumour
cells with the immune system of the host, we retransfected
TSA-IFN-6000 cells with allogeneic H-2K6 or H-2D" genes to
exploit the high expression of IFN-induced molecules in
TSA-IFN-- clones. Moreover, since IFN--I transfectants
appeared to stimulate macrophages more than T cells, the
addition of allogeneic MHC antigens could tip the balance in
favour of a T response, mainly through the release of
b
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Figure 3 Lack of therapeutic effect on TSA-pc lung metastases in nude mice. Mice challenged with 5 x 105 live TSA-pc cells i.v.
received six ilnjections of 10 MitC cells s.c. in a thigh. (a) Metastasis-free mice number of treated mice. (b) Range of lung
metastases.
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Figure 4 Therapy of TSA-pe lung metastases with IFN-,; transfectants administered iv; BALB c mice challenged with 5 x 1 live
TSA-pc cells i.v. received six injections of 106 MitC cells i.v. (a) Metastasis-free mice number of treated mice. (b) Range of lung
metastalses. *Number of metastases significantly different (P<0.0l aIt least) from untreated or TSA-pc-treated mice by Wileoxon's
rallnk-sum test.
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Figure 6 Lysis ofTSA-pc by lymph node cells from BALB/c mice
repeatedly immunised with double transfectants without in vitro
restimulation.
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OEM activity was 3-4 times higher than that of lymphocytes of
I I mice immunised with TSA-IFNy'. Unprimed macrophages
102 103 showed a very high cytotoxic activity against all cells
,scence releasing IFN-y, regardless of allogeneic MHC expression
(Lollini et al., 1995).
MitC double transfectant cells were used to treat mice that bexpression had received live TSA-pc cells i.v. (Figure 7). TSA-
IFNy6" -Db was more effective than the TSA-IFNyl0
clone. Moreover, the rejection of double transfectant
Kb tumours by the host enabled us to compare proliferating
b cells and MitC cells. When administered as proliferating cells, D H-2Db transfectant cells were significantly more effective than
TSA-IFNy6000. Note that the control cells shown in Figure 7,
i.e. TSA-IFNy600 and the hygro transfectant, could not be
used without mitomycin treatment, since they gave rise to
progressive tumours at the site of injection. No therapeutic
effect by TSA-IFNy6000-Db was observed in nude mice,
confirming the requirement of an intact T-cell response for
""I ""I the cure of lung metastases (data not shown). No mouse
102 103 treated with TSA-pc cells transfected with an allogeneic
10cence MHC gene alone was cured (data not shown). It should be
noted that allogeneic MHC expression of double transfec-
ression of double tants was 70 times higher than expression of cells transfected
as IUml-172h-1 with the MHC gene alone in the absence of autocrine
2 expression was induction by IFN-y.
eported (Lollini et
Discussion
autocrine/paracrine helper cytokines by alloreactive lympho-
cytes.
The expression of allogeneic H-2b antigens obtained after
transfection ofTSA-IFNy6" was indeed very high (Figure 5).
Similar transfections yielded only clones expressing low levels
of H-2 antigens, when cells which do not produce IFN-y were
used as recipients (De Giovanni et al., 1994). Other in vitro
growth characteristics of double transfectants did not differ
from those of parent TSA-IFNyl0 cells. In vivo, both the
tumorigenicity and the metastatic ability of double transfec-
tants in immunocompetent mice were almost completely
abolished (Lollini et al., 1995); both T cells and macrophages
were found to be involved in the rejection of these cells. In
nude mice the tumorigenic potential of double transfectants
was similar to that of control or parental cells, thus
confirming the role played by T cells (Lollini et al., 1995).
Lymphocytes of mice immunised with cells transfected
with IFN-y plus H-2 genes killed TSA-pc target cells even
without in vitro restimulation (Figure 6), and their cytotoxic
TSA is a highly malignant and poorly immunogenic mammary
adenocarcinoma spontaneously arisen in a BALB/c mouse
(Lollini et al., 1993). TSA is quite refractory to conventional
chemotherapy and immunotherapy, and reproduces many
features of human mammary carcinomas (De Giovanni et al.,
1988; Deabate etal., 1992), thus it is a realisticmodel ofhuman
neoplasms. TSA cells have been used as recipients for many
genes relevant to gene therapy oftumours, and it is one ofthe
few systems available for comparative studies (Colombo and
Forni, 1994; Allione et al., 1994). In this paper we have shown
that repeated injections of MitC IFN-y and allogeneic MHC
class I gene-transduced TSA cells were effective in inhibiting
lung metastases.
IFN-y receptors are ubiquitous, thus gene therapy with
IFN genes will bring about phenotypic modifications of the
target cell along with immunomodulation of the host. We
have shown here that the autocrine effects can be rationally
exploited to devise specific therapeutic modalities. Tumour
cells transduced with the IFN-y gene, as well as cells treated
with exogenous IFN-y, generally show a tremendous increase,
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Figure 7 Therapy of TSA-2c lung metastases with double transfectants. BALB/c mice challenged with 5 x 104 live TSA-pc cells i.v.
received six injections of 10 MitC (_) or untreated (E) cells s.c. in a thigh. (a) Metastasis-free mice/number of treated mice. (b)
Range of lung metastases. Number of metastases significantly different (P<0.05 at least) from untreated mice (*) or from mice
immunised with TSA-IFNy6000 (#) by Wilcoxon's rank-sum test.
both in the expression of some IFN-sensitive genes, including
MHC (Watanabe et al., 1989; Gansbacher et al., 1990; Chen
and Ananthaswamy, 1993; Mizuno et al., 1994), and in the
ability to colonise the lung after i.v. injection (Lollini et al.,
1993). The latter is linked to the former via a decrease in
sensitivity to NK cells (Kelly et al., 1991). Since TSA-IFN-y
transfectants maintain the selective homing to the lung of
TSA-pc metastases, we injected MitC transfectants i.v. to
obtain a selective delivery of IFN-y to TSA-pc metastatic
sites. In this way a significant therapeutic effect, but not
immune memory, was obtained. Therefore, the function of
TSA-IFN-y clones in this setup was to act mainly as
'micropumps', effectively targeting the released IFN-y to the
lung and eliciting mainly a local response.
The results obtained after i.v. therapy indicated that a local
stimulation of inflammatory cells could significantly reduce
metastatic load, but no single mouse was completely free from
metastases. Single and double transfectants administered s.c.
showed a higher therapeutic efficacy, with 30-80% ofmice free
from detectable metastatic nodules. This supports the idea that
engineered tumour cells elicit a cross-talk between non-specific
effectors and T lymphocytes, leading to a rapid destruction of
tumour cells at the site of cytokine release and to the
establishment of a systemic, long-term T-cell response that
can reach and destroy distant metastatic deposits (Colombo et
al., 1992). Local tumour control can be effected by different
inflammatory responses elicited by engineered tumour cells
(Musiani et al., 1996); however, the expansion of an optimal T-
cell reactivity is not always obtained (Colombo et al., 1992).
Our results show that both the route ofvaccination and the use
ofadditional antigenic stimuli can tip the balance in favour ofa
curative T-cell response.
The autocrine stimulation of genes containing IFN
response elements in IFN-y-transduced cells suggested that
these cells could also be used as efficient recipients of IFN-
sensitive genes. The allogeneic MHC genes, H-2K' and H-
2Db, were used to confer upon IFN-y transfectants an
additional immunogenic signal. In the TSA model, IFN-y
induced mainly a local macrophage response (Lollini et al.,
1993; Musiani et al., 1994); allogeneic MHC gene products
stimulate many T lymphocytes, and double IFN-y plus MHC
gene transfectants were found to stimulate both macrophages
and T lymphocytes simultaneously (Lollini et al., 1995).
Moreover, IFN-y plus MHC double transfectants were non-
tumorigenic in immunocompetent mice, unlike IFN-y single
transfectants, and could be used as a live vaccine, which was
therapeutically more effective than MitC cells, thus confirm-
ing our previous findings with TSA cells transduced with
various cytokine genes (Allione et al., 1994).
Two issues deserve further discussion. Pleiotropic cyto-
kines, such as IFN-y, preferentially stimulate distinct immune
response mechanisms in different tumour model systems. In
effect, cells transduced with the IFN-y gene were found to
stimulate either T cells (Watanabe et al., 1989; Esumi et al.,
1991; Teramura et al., 1993) or macrophages selectively
(Gansbacher et al., 1990; Lollini et al., 1993; Hock et al.,
1993), apparently in an unpredictable way. The IFN-y and
allo-MHC double transfection approach showed that, when
IFN-y-activated response depends on macrophages, the
presence of allogeneic MHC elicits a T-cell response. The
two MHC genes used in TSA transfectants did not yield
identical results: H-2Db was more effective than H-2Kb in the
therapeutical setup, possibly due to the fact that H-2Kb
transfectants are more rapidly rejected by the host (Lollini et
al., 1995), and thus do not persist in vivo long enough to
induce systemic immunity. The differential effect of H-2K'
and H-2Db suggests that gene therapy approaches based on
the transduction of allogenic MHC genes may be further
refined and optimised by selecting the most effective MHC
regions and alleles, possibly on the basis of the MHC
haplotypes of each patient.
Present data acquire particular importance, since several
phase I clinical trials using gene-transduced tumour cells are
in progress, while the real efficacy of this approach is still
controversial (Colombo and Forni, 1994). About 50 different
cell lines have been transduced worldwide with genes coding
for IFN-y; however, the number of studies actually dealing
with therapeutic protocols is still quite small. The therapeutic
efficacy obtained in our model was similar to that attained in
the Lewis lung carcinoma system (Porgador et al., 1993);
other studies with MBT-2 bladder carcinoma (Connor et al.,
1993) and Dunning rat prostate carcinoma (Vieweg et al.,
1994) reported a limited therapeutic success with IFN-y-
secreting cells. The studies present a number of common
features: all used realistic models of malignant carcinomas;
the therapeutic schedule comprised multiple administrations
of similar doses of IFN-y-transduced cells; and therapeutic
vaccinations started when neoplastic deposits (either local or
metastatic) were quite small. As a whole, these results suggest
that a gene therapy approach based on IFN-y is feasible and
can be successful when the tumour load is small or metastatic
deposits are still in the infancy of their natural history.
Moreover, a rational exploitation of the biological properties
of genetically engineered cells can further ameliorate the
success rate obtained with the straightforward protocols
adopted by earlier studies.
Finally, a crucial point of gene therapy with cytokine
genes is which cytokine gives the best therapeutic results. No
b
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common pattern has emerged from comparative studies
conducted using different experimental model systems
(Dranoff et al., 1993; Hock et al., 1993; Allione et al.,
1994; Franco et al., 1994), but interferons, together with
some interleukins and colony-stimulating factors, are clearly
among the most promising candidates for this type of gene
therapy. The early experimental work on cells transduced
with genes coding for each individual cytokine aided in
designing the currently ongoing phase I protocols. More
extensive experimental studies are now required in which
different genes, coding for cytokines or antigens, are
compared in different tumour types, to obtain useful
information for the design of phase II gene therapy studies
in humans.
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